See more : Strategic Global Investments, Inc. (STBV) Income Statement Analysis – Financial Results
Complete financial analysis of Bioray Biotech Co., Ltd (7561.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bioray Biotech Co., Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Lagardere SA (MMB.PA) Income Statement Analysis – Financial Results
- Endurance Gold Corporation (ENDGF) Income Statement Analysis – Financial Results
- ZEAL Network SE (0QJQ.L) Income Statement Analysis – Financial Results
- Abirami Financial Services (India) Limited (ABIRAFN.BO) Income Statement Analysis – Financial Results
- Southwest Securities Co., Ltd. (600369.SS) Income Statement Analysis – Financial Results
Bioray Biotech Co., Ltd (7561.TWO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bio-ray.com.tw
About Bioray Biotech Co., Ltd
Bioray Biotech Co., Ltd engages in the research and development, manufacture, and sale of biological and health supplement products. Its biological products include functional probiotics, medicinal fungi, and immune cell preparations. The company is also involved in the cell testing and storage business. Bioray Biotech Co., Ltd was founded in 1994 is based in Pingtung, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 191.83M | 190.60M | 148.02M | 156.30M | 181.93M |
| Cost of Revenue | 114.18M | 110.09M | 80.73M | 88.44M | 100.66M |
| Gross Profit | 77.65M | 80.51M | 67.29M | 67.86M | 81.28M |
| Gross Profit Ratio | 40.48% | 42.24% | 45.46% | 43.42% | 44.67% |
| Research & Development | 44.27M | 32.26M | 21.86M | 14.41M | 12.09M |
| General & Administrative | 20.63M | 21.25M | 30.48M | 43.56M | 54.32M |
| Selling & Marketing | 32.10M | 27.24M | 23.07M | 9.80M | 8.11M |
| SG&A | 52.73M | 48.48M | 53.55M | 53.36M | 62.34M |
| Other Expenses | 0.00 | 2.17M | 2.84M | -195.00K | 0.00 |
| Operating Expenses | 96.98M | 80.75M | 75.40M | 67.77M | 58.63M |
| Cost & Expenses | 211.16M | 190.83M | 156.13M | 156.20M | 159.29M |
| Interest Income | 648.00K | 191.00K | 53.00K | 135.00K | 184.00K |
| Interest Expense | 1.32M | 1.36M | 953.00K | 1.17M | 1.12M |
| Depreciation & Amortization | 25.00M | 22.23M | 19.08M | 15.28M | 8.40M |
| EBITDA | 12.14M | 24.27M | 13.86M | 14.99M | 15.25M |
| EBITDA Ratio | 6.33% | 12.78% | 9.37% | 9.79% | 8.38% |
| Operating Income | -19.33M | 2.12M | -5.22M | 31.00K | 6.85M |
| Operating Income Ratio | -10.08% | 1.11% | -3.53% | 0.02% | 3.76% |
| Total Other Income/Expenses | 5.14M | 995.00K | 1.94M | -1.46M | 14.86M |
| Income Before Tax | -14.19M | 682.00K | -6.17M | -1.46M | 21.71M |
| Income Before Tax Ratio | -7.40% | 0.36% | -4.17% | -0.93% | 11.93% |
| Income Tax Expense | -2.63M | 182.00K | 1.76M | -42.00K | 7.98M |
| Net Income | -11.56M | 500.00K | -7.19M | -58.00K | 19.49M |
| Net Income Ratio | -6.03% | 0.26% | -4.86% | -0.04% | 10.71% |
| EPS | -0.38 | 0.02 | -0.27 | 0.00 | 0.71 |
| EPS Diluted | -0.38 | 0.02 | -0.27 | 0.00 | 0.71 |
| Weighted Avg Shares Out | 30.09M | 28.02M | 26.77M | 27.41M | 27.41M |
| Weighted Avg Shares Out (Dil) | 30.09M | 28.02M | 26.77M | 27.42M | 27.44M |
Source: https://incomestatements.info
Category: Stock Reports